8-K: bioAffinity Launches Study to Expand CyPath Lung Options

bioAffinity Technologies announced a new study with Brooke Army Medical Center to validate the use of CyPath Lung with deep suction sputum samples for early lung cancer detection.

Summary

• bioAffinity Technologies initiated a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of CyPath Lung.
• The study aims to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer.
• This validation has the potential to expand sample collection options for the noninvasive CyPath Lung diagnostic test.
• The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning.
• Results from the study are anticipated by mid-year 2026.
• CyPath Lung is currently used with at-home collected sputum samples for high-risk patients with suspicious pulmonary nodules.
• The test has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules less than 20 millimeters.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the new study has the potential to significantly expand the market and utility of CyPath Lung, addressing a clear clinical need and leveraging existing medical procedures.

Positives

• The new study with BAMC could expand CyPath Lung's versatility and support broader use in early-stage lung cancer detection.
• The approach leverages existing medical procedures like bronchoscopy and tracheal/bronchial suctioning for sample collection, potentially accelerating adoption.
• The study addresses clinicians' expressed need for additional tools for diagnosing indeterminate lung nodules.
• Collaboration with Brooke Army Medical Center, a premier academic medical center and leader in medical research, enhances credibility and access to a large patient population.

Risks

• The timing, design, enrollment, conduct, and anticipated results of the Brooke Army Medical Center study may not meet expectations.
• The clinical utility, performance, versatility, or broader adoption or use of CyPath Lung, including its use with deep suction samples, may not materialize as anticipated.
• The potential benefits, applications, market opportunity, or impact of CyPath Lung or related technologies may not be realized.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC could materially affect actual results.

Future Outlook

The company anticipates that validating CyPath Lung's performance on deep suction samples will expand its versatility and support broader use in early-stage lung cancer detection. Results from the BAMC study are expected by mid-year 2026, potentially accelerating and expanding the adoption of CyPath Lung by offering more convenient sample collection methods.

Management Comments

• "The ability to use CyPath Lung to analyze suctioned sputum collected during bronchoscopy and other procedures would leverage samples that we are already obtaining and expand access to earlier, more informed decision-making for patients at risk." Michael J. Morris, MD, Pulmonology and Critical Care Physician at BAMC.
• "Physicians tell us they need additional tools for diagnosing indeterminate lung nodules, and this study demonstrates that we are listening to the clinicians using CyPath Lung and responding to their needs." Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies.
• "We look forward to collaborating with BAMC and the potential to expand the reach of the AI-driven technology behind CyPath Lung to detect lung cancer at the earliest, most treatable stage." Maria Zannes, President and CEO of bioAffinity Technologies.

Industry Context

StockSavvy.ai notes that this study positions bioAffinity Technologies to tap into the significant and growing U.S. bronchoscopy market, valued at $700-$920 million annually. By integrating CyPath Lung with existing bronchoscopy procedures, the company aims to offer a complementary diagnostic tool that addresses a clear clinical need for improved early detection of lung cancer, aligning with broader trends in noninvasive diagnostics and AI-driven medical technology.

Comparison to Industry Standards

• The U.S. bronchoscopy procedure market, including devices and related technologies, is valued at $700-$920 million annually, indicating a substantial and growing market driven by the rising prevalence of lung disease, including cancer and COPD.
• CyPath Lung's reported clinical study results of 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in high-risk patients with small indeterminate lung nodules (<20mm) are strong indicators of its diagnostic potential, though direct comparisons to specific competitor products or global benchmarks are not provided in this filing.

Stakeholder Impact

• Shareholders: Potential for increased market adoption and revenue if the study is successful, leading to long-term value creation.
• Patients: Expanded access to an earlier, noninvasive lung cancer detection method, potentially leading to improved treatment outcomes.
• Clinicians: Provides an additional, complementary tool for diagnosing indeterminate lung nodules, leveraging existing procedures.
• Brooke Army Medical Center: Strengthens its role as a leader in medical research and provides advanced diagnostic capabilities for its patient population.

Next Steps

• Enroll approximately 30-50 patients in the BAMC study.
• Anticipate study results by mid-year 2026.

Key Dates

Recommendation

The announcement of a new study to expand the utility of CyPath Lung is a positive strategic move that could broaden its market reach and adoption. However, the impact on the company's financials is contingent on the study's successful completion and positive results, which are not expected until mid-2026. Therefore, a "hold" recommendation is appropriate, awaiting further data and commercialization progress.

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer detection, noninvasive diagnostic, early cancer detection, Brooke Army Medical Center, sputum samples, tracheal suctioning, bronchial suctioning, biotechnology, medical research, AI-driven diagnostics, pulmonary nodules, bronchoscopy